New Diabetes Treatments-Enhanced blood flow

Three diabetes treatments with entirely new modes of action were approved: exenatide injection for people with type 2 diabetes, pramlintide injection as an add-on to insulin therapy for people with type 1 or type 2 diabetes and Sitagliptin also for people with type 2 diabetes. Some diabetes medications help the pancreas release more insulin (if you have type 2 diabetes), others help cells use insulin better, and others keep the liver from releasing too much glucose. The new treatments focus action on hormones called incretins.
Exenatide injection:

  • is injected twice a day at mealtime
  • is for those with type 2 diabetes who have been unable to control blood glucose with oral medicines
  • improves blood glucose control by mimicking incretin hormones, stimulating insulin and slowing stomach-emptying
  • leads to weight loss because patients will feel full faster and stop eating
  • can cause nausea

Exenatide extended release  is  injected once per week is for those with type 2 diabetes who have been unable to control blood glucose with oral medicines  that helps to improves blood glucose control by mimicking incretin hormones, stimulating insulin and slowing stomach-emptying leads to weight loss because patients will feel full faster and stop eating which can cause nausea.

Pramlintide acetate is intended for those with type 1 or type 2 diabetes who use insulin

  • is injected at mealtime
  • is to never mix with insulin in one syringe; which creates the need for an additional injection for the patient
  • used for better glucose control, reduction in blood glucose spikes, reduction in food intake, whichleads to weight loss
  • can cause nausea or hypoglycemia (dangerously low blood glucose)

Sitagliptin Saxagliptin and linagliptin-All three of these pills

  • are taken once a day
  • are for type 2 diabetes
  • do not promote weight gain
  • are often used in combination with metformin
  • have very little, if any, side effects
  • Should be taken with caution for patients with renal disease (dose should be decreased)
  • slows the breakdown of incretins, so insulin is released over a longer period of time

  • Liraglutide Injection
  • Exenatide Injection
  • Exenatide extended release Injection
  • Pramlintide acetate(Mealtime Injection)
  • Sitagliptin and Metformin (Dipeptidyl Peptidase-4 Inhibitors)
  • Saxagliptin and Metformin
  • Linagliptin and Metformin

Related Conference of New Diabetes Treatments-Enhanced blood flow

November 21-22, 2018

14th World Congress on Endocrinology & Diabetes

Paris, France
November 26-27, 2018

26th International Diabetes and Healthcare Conference

Helsinki, Finland
November 26-27, 2018

13th European Diabetes and Endocrinology Congress

Dublin, Ireland
February 27-28, 2019

Asia Pacific Diabetes and Endocrinology Congress

Radisson Hotel Narita, Tokyo, Japan

April 17-18, 2019

21st Asia Pacific Diabetes Conference

Osaka,Japan
May 17-18, 2019

2nd Global Experts Meeting on Diabetes, Hypertension & Metabolic Syndrome

Holiday Inn Singapore Atrium | Singapore
May 30-31, 2019

2nd Global Meeting on Diabetes and Endocrinology

Istanbul, Turkey
June 10-11, 2019

28th European Diabetes Congress

| Edinburgh, Scotland
July 24-25, 2019

29th World Diabetes & Heart Congress

Melbourne, Australia
July 29-30, 2019

12th International Conference on Diabetes & Metabolism

Chicago | Illinois| USA
Oct 03-04, 2019

Euro Diabetes Congress & Expo

| Paris, France

New Diabetes Treatments-Enhanced blood flow Conference Speakers

Recommended Sessions

Related Journals

Are you interested in